Eisai Inc v. Sanofi Aventis U.S. LLC
Eisai Inc v. Sanofi Aventis U.S. LLC, 14-2017
In an antitrust suit alleging the conduct of defendant harmed competition in the market for anticoagulant drugs by preventing hospitals from replacing Lovenox, one of defendant’s drugs with competing drugs, the District Court’s grant of summary judgment to defendant is affirmed where, analyzing plaintiff’s claims under the rule of reason, there is no evidence that defendant’s actions caused broad harm to the competitive nature of the anticoagulant market.
- Published 2016/05/04
- United States Third Circuit